|Mr. Fabio Chianelli||CEO & Chairman||N/A||N/A||1978|
|Mr. Carmelo Marrelli ACIS, B.Comm., CA, CGA, CPA||Chief Financial Officer||N/A||N/A||1971|
|Mr. Andrew Todd||Corp. Sec.||N/A||N/A||1958|
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of ketamine and microneedle patches for delivering psychedelics to treat neuropsychiatric, neurodegenerative, and pain disorders. The company's products in pipeline include Ketamine, which is in Phase I and II clinical trials for Parkinson's disease indications, as well as in preclinical trials for ALS-Lou Gehrig's disease indications; and KETABET, which is in Phase I and II clinical trials for depression indications. It is also developing microneedle patches for the delivery of antivirals for the treatment of influenza; and NCEs for multiple indications. The company is headquartered in Vancouver, Canada.
PharmaTher Holdings Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.